{"id":4143,"date":"2025-03-31T18:11:59","date_gmt":"2025-03-31T18:11:59","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/levomepromazine-txt\/"},"modified":"2025-03-31T18:11:59","modified_gmt":"2025-03-31T18:11:59","slug":"levomepromazine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/levomepromazine-txt\/","title":{"rendered":"Levomepromazine.txt"},"content":{"rendered":"

Levomepromazine <\/h1>\n

CLINICAL USE <\/H3>
\nTreatment of schizophrenia Adjunctive treatment in palliative care Nausea and vomiting

DOSE IN NORMAL RENAL FUNCTION <\/H3>Schizophrenia: Oral, initially 25\u201350 mg daily, increasing to 100\u2013200 mg in 3 divided doses; maximum dose 1 g dailyPalliative care: Oral: 12.5\u201350 mg every 4\u20138 hours \u2014IM\/IV: 12.5\u201350 mg every 6\u20138 hours \u2014SC Infusion: 5\u2013200 mg daily \u2014

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :328.5<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 1<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :23\u201342<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :30\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Start with small dose and increase as necessary

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced hypotensive effect\n
  • Analgesics: increased risk of convulsions with tramadol; increased hypotension and sedation with opioid analgesics\n
  • Anti-arrhythmics: increased risk of ventricular arrhythmias due to prolongation of QT interval; increased risk of ventricular arrhythmias with amiodarone \u2013 avoid concomitant administration\n
  • Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin \u2013 avoid concomitant administration\n
  • Antidepressants: possibly increased plasma level of tricyclics, increased antimuscarinic effects and ventricular arrhythmias; avoid concomitant administration with MAOIs (2 fatalities have been reported)Anticonvulsant: lowers anticonvulsant threshold\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine\n
  • Antipsychotics: increased risk of ventricular arrhythmias with pimozide \u2013 avoid concomitant use\n
  • Antivirals: plasma concentration possibly increased by ritonavirAntihypertensives: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalolAnxiolytics and hypnotics: increased sedation\n
  • Diuretics: enhanced hypotensive effect\n
  • Lithium: increased risk of extrapyramidal effects and neurotoxicity\n
  • Pentamidine: increased risk of ventricular arrhythmias \u2013 avoid concomitant use\n
  • Sibutramine: increased risk of CNS toxicity \u2013 avoid concomitant useLevomepromazine (methotrimeprazine).LEVoMEProMAZinE (METhoTriMEPrAZinE) 433

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral, IV, IM, SC

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>For a subcutaneous infusion dilute in sodium chloride 0.9% and give via a syringe driverCompatible with diamorphine For IV injection, dilute with an equal volume of sodium chloride 0.9%

    OTHER INFORMATION <\/H4>In renal disease there is an increased risk of cerebral sensitivity
    \n","protected":false},"excerpt":{"rendered":"

    Levomepromazine CLINICAL USE Treatment of schizophrenia Adjunctive treatment in palliative<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4143","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4143"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4143\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}